丁苯酞胶囊治疗脑梗死进展性神经功能障碍的疗效观察
|
摘要
目的探讨丁苯酞胶囊治疗脑梗死进展性神经功能障碍的疗效观察。方法根据随机数字表法将2016年1月至2018年6月期间来本院治疗的80例进展性脑梗死患者分为对照组与研究组,每组各40例。两组患者均给予相同方案的基础治疗,研究组在基础治疗同时联合丁苯酞胶囊治疗,两组患者连续观察治疗2周。观察比较两组进展性脑梗死患者治疗前、治疗1周后与2周后Barthel指数评分(BI评分)情况、美国国立卫生研究院卒中量表评分(NIHSS评分),对两周后患者的疗效情况进行分析比较。结果纳入研究的进展性脑梗死患者治疗后,BI评分升高,研究组BI评分高于对照组(P<0.05);纳入研究的进展性脑梗死患者NIHSS评分随着治疗时间越长降低越明显,研究组NIHSS评分明显低于对照组(P<0.05);经两周治疗后,研究组总有效率为92.50%明显高于对照组的82.50%,差异有统计学意义(P<0.05)。结论丁苯酞胶囊能有效治疗脑梗死进展性神经功能障碍,提高患者神经功能,提高患者日常生活质量,值得临床推广。
Objective To investigate the efficacy of bupropion capsules in the treatment of progressive neurological dysfunction in patients with cerebral infarction. Methods According to the random number table method, 80 patients with progressive cerebral infarction who were treated in our hospital from January 2016 to June 2018 were divided into control group and study group, with 40 patients in each group. The two groups of patients were given the same treatment as the basic treatment, but the study group was treated with butylphthalide capsules in the basic treatment, and the two groups were continuously observed for 2 weeks. To observe and compare the Barthel index score(BI score) before treatment, 1 week after treatment and 2 weeks after treatment, and the National Institutes of Health Stroke Scale score(NIHSS score) for patients with progressive cerebral infarction.The situation was analyzed and compared. Results After treatment in patients with progressive cerebral infarction, the BI score increased, and the BI score of the study group was higher than that of the control group(P<0.05). The NIHSS score of patients with progressive cerebral infarction included in the study decreased with the treatment time. Obviously, the NIHSS score of the study group was significantly lower than that of the control group(P<0.05). After two weeks of treatment, the total effective rate of the study group was 92.50%, which was significantly higher than that of the control group(82.50%). The difference was statistically significant(P<0.05). Conclusion Butylphthalide capsule can effectively treat progressive neurological dysfunction in cerebral infarction, improve neurological function and improve the quality of daily life of patients. It is worthy of clinical promotion.
Objective To investigate the efficacy of bupropion capsules in the treatment of progressive neurological dysfunction in patients with cerebral infarction. Methods According to the random number table method, 80 patients with progressive cerebral infarction who were treated in our hospital from January 2016 to June 2018 were divided into control group and study group, with 40 patients in each group. The two groups of patients were given the same treatment as the basic treatment, but the study group was treated with butylphthalide capsules in the basic treatment, and the two groups were continuously observed for 2 weeks. To observe and compare the Barthel index score(BI score) before treatment, 1 week after treatment and 2 weeks after treatment, and the National Institutes of Health Stroke Scale score(NIHSS score) for patients with progressive cerebral infarction.The situation was analyzed and compared. Results After treatment in patients with progressive cerebral infarction, the BI score increased, and the BI score of the study group was higher than that of the control group(P<0.05). The NIHSS score of patients with progressive cerebral infarction included in the study decreased with the treatment time. Obviously, the NIHSS score of the study group was significantly lower than that of the control group(P<0.05). After two weeks of treatment, the total effective rate of the study group was 92.50%, which was significantly higher than that of the control group(82.50%). The difference was statistically significant(P<0.05). Conclusion Butylphthalide capsule can effectively treat progressive neurological dysfunction in cerebral infarction, improve neurological function and improve the quality of daily life of patients. It is worthy of clinical promotion.
引文
[1]方兰,许俊,苏静霞.进展性脑梗死的相关危险因素分析[J].当代医学,2018,24(18):57-59.
[2]孙元元,李慧,郎文娟,等.丁苯酞对急性脑梗死的治疗作用[J].临床荟萃,2016,31(2):182-186.
[3]《中国实用神经疾病杂志》2015年总目次[J].中国实用神经疾病杂志,2015,18(24):1-40.
[4]陆吕平,张国庆,顾伯林,等.中西医结合治疗对缺血性脑卒中老年患者的BARTHEL指数评分、神经功能缺损评分及血液流变学的影响[J].中国老年学杂志,2014,34(1):83-85.
[5]美国国立卫生研究院脑卒中量表(NIHSS)简介[J].临床荟萃,2009,24(8):685.
[6]戴海琳,王丽,王彦珍,等.丁苯酞氯化钠注射液联合双重抗血小板治疗进展性脑梗死的临床疗效观察[J].中国现代医学杂志,2015,25(33):95-97.
[7]高星乐,陈力宇,孙乐球,等.依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(16):1569-1571.
[8]端木寅,王源,梁爽,等.丁苯酞脑缺血治疗作用的相关药理学研究进展[J].中药药理与临床,2012,28(3):126-130.
[9]潘君枝,程超禅,陈瑞炳.丁苯酞治疗对急性脑梗死患者血管内皮功能与血栓形成的影响[J].中国老年学杂志,2015,35(13):3580-3582.
[10]宋晓明,郑珍婕,苏立静,等.丁苯酞序贯治疗对急性进展性脑梗死患者神经功能、炎症因子及Hcy、NSE的影响[J].中华全科医学,2017,15(3):434-436.
[2]孙元元,李慧,郎文娟,等.丁苯酞对急性脑梗死的治疗作用[J].临床荟萃,2016,31(2):182-186.
[3]《中国实用神经疾病杂志》2015年总目次[J].中国实用神经疾病杂志,2015,18(24):1-40.
[4]陆吕平,张国庆,顾伯林,等.中西医结合治疗对缺血性脑卒中老年患者的BARTHEL指数评分、神经功能缺损评分及血液流变学的影响[J].中国老年学杂志,2014,34(1):83-85.
[5]美国国立卫生研究院脑卒中量表(NIHSS)简介[J].临床荟萃,2009,24(8):685.
[6]戴海琳,王丽,王彦珍,等.丁苯酞氯化钠注射液联合双重抗血小板治疗进展性脑梗死的临床疗效观察[J].中国现代医学杂志,2015,25(33):95-97.
[7]高星乐,陈力宇,孙乐球,等.依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(16):1569-1571.
[8]端木寅,王源,梁爽,等.丁苯酞脑缺血治疗作用的相关药理学研究进展[J].中药药理与临床,2012,28(3):126-130.
[9]潘君枝,程超禅,陈瑞炳.丁苯酞治疗对急性脑梗死患者血管内皮功能与血栓形成的影响[J].中国老年学杂志,2015,35(13):3580-3582.
[10]宋晓明,郑珍婕,苏立静,等.丁苯酞序贯治疗对急性进展性脑梗死患者神经功能、炎症因子及Hcy、NSE的影响[J].中华全科医学,2017,15(3):434-436.